Sharing on behalf of Dr. Kim Nichols,
Dear NICER colleagues, In collaboration with the North American Consortium for Histiocytosis (NACHO), Melissa Hines and I are running a clinical trial investigating the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for children with newly diagnosed or relapsed/refractory HLH. The protocol is now open at 10 participating sites, including:
St. Jude Children’s Research Hospital – Memphis, TN
Children’s Hospital of Philadelphia – Philadelphia, PA
UCSF Benoiff Children’s Hospital – San Francisco, CA
Children’s Hospital of Orange County – Orange , CA
Phoenix Children’s Hospital – Phoenix, AZ
Atrium Health Levine Children’s Hospital – Charlotte, NC
Children’s National Medical Center – Washington, DC
Children’s Wisconsin – Milwaukee, WI
Cohen Children’s Medical Center – New Hyde Park, NY
· Johns Hopkins – Baltimore, MD You can also find more information at: HLHRUXO clinical trial and at: https://clinicaltrials.gov/ct2/show/NCT04551131?term=ruxolitinib&cond=HLH&draw=2&rank=3
We are excited to have this study open and are willing to address any questions that you or your colleagues might have.
Please feel free to refer your patients to St. Jude for or to any of the above centers for potential enrollment. If you have a patient and are interested in learning more, please see the attached flyer or contact the study team at HLHRUXO@stjude.org. Thank you very much for your kind consideration, Kim
Kim E. Nichols, MD
Director, Division of Cancer Predisposition
St. Jude Children’s Research Hospital
(901) 484-7789 – cell (preferred)
(901) 595-8385 – office
(901) 595-6086 – fax
https://www.stjude.org/directory/n/kim-nichols.html
https://www.stjude.org/research/labs/nichols-lab.html
